OncoTherad® is an immunomodulator of biological response that downregulate RANK/RANKL signaling pathway and PD-1/PD-L1 immune checkpoint in non-muscle invasive bladder cancer

Author:

Reis Ianny Brum,Tibo Luiz Henrique Soares,de Souza Bianca Ribeiro,Durán Nelson,Fávaro Wagner José

Funder

Coordenação de Aperfeiçoamento de Pessoal de Nível Superior

Fundação de Amparo à Pesquisa do Estado de São Paulo

Conselho Nacional de Desenvolvimento Científico e Tecnológico

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology,General Medicine

Reference91 articles.

1. Aerts J, Lievense L, Hoogsteden H, Hegmans J (2013) Immunotherapy prospects in the treatment of lung cancer and mesothelioma. Transl Lung Cancer Res 3:34–45

2. Ahern E, Smyth MJ, Dougall WC, Teng MWL (2018) Roles of the RANKL–RANK axis in antitumour immunity—implications for therapy. Nature Rev Clin Oncol 15:676–693

3. Akiyama T, Shimo Y, Yanai H, Qin J, Ohshima D, Maruyama Y et al (2008) The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance. Immunity 29:423–437

4. Akiyama T, Shinzawa M, Qin J, Akiyama N (2013) Regulations of gene expression in medullary thymic epithelial cells required for preventing the onset of autoimmune diseases. Front Immunol 4:249

5. American Cancer Society (2021) Overview: bladder cancer. In: What are the key statistics about bladder cancer? American Cancer Society, Atlanta. http://www.cancer.org/cancer/bladdercancer/detailedguide/bladder-cancer-key-statistics. Accessed 2 May 2021

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3